Antibody-lectin chimeras for glyco-immune checkpoint blockade
J. C. Stark, M. A. Gray, S. Wisnovsky, I. Ibarlucea-Benitez, M. Lustig, N. M. Riley, M. K. Ribi, W. J. Errington, B. Bruncsics, C. A. Sarkar, T. Valerius, J. V. Ravetch, C. R. Bertozzi
This paper introduces antibody-lectin chimeras (AbLecs) as a new immunotherapy approach that blocks glyco-immune checkpoints, enhancing cancer immune responses and synergizing with existing checkpoint inhibitors.
bioRxiv · Oct 26, 2022Bioengineering